Vimian Group AB (publ) (VIMGF)
OTCMKTS · Delayed Price · Currency is USD
2.770
0.00 (0.00%)
At close: Dec 17, 2025
Vimian Group AB Revenue
Vimian Group AB had revenue of 104.30M EUR in the quarter ending September 30, 2025, with 19.06% growth. This brings the company's revenue in the last twelve months to 421.00M, up 19.49% year-over-year. In the year 2024, Vimian Group AB had annual revenue of 374.80M with 12.99% growth.
Revenue (ttm)
421.00M EUR
Revenue Growth
+19.49%
P/S Ratio
3.57
Revenue / Employee
350.83K EUR
Employees
1,200
Market Cap
1.76B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 374.80M | 43.10M | 12.99% |
| Dec 31, 2023 | 331.70M | 50.39M | 17.91% |
| Dec 31, 2022 | 281.31M | 107.96M | 62.28% |
| Dec 31, 2021 | 173.35M | 102.12M | 143.37% |
| Dec 31, 2020 | 71.23M | 46.70M | 190.36% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Northwest Biotherapeutics | 937.00K |
Vimian Group AB News
- 2 months ago - Vimian Group AB (publ) (VIMGF) Q3 2025 Earnings Call Transcript - Seeking Alpha